Preview

South Russian Journal of Cancer

Advanced search

Experience of stereotactic radiation therapy and radiosurgical treatment of metastatic vertebral tumors

https://doi.org/10.37748/2686-9039-2024-5-2-1

EDN: gjahux

Abstract

Purpose of the study. Evaluation of the effectiveness of extracranial stereotactic radiation therapy in various fractionation regimens in the treatment of patients with metastatic vertebral lesions.

Patients and methods. The study included 12 patients with metastatic spinal lesions who underwent extracranial stereotactic radiation therapy (SBRT) on a Novalis Tx linear accelerator, Varian, in radiosurgery mode (SRS; in 1 fraction) and hypofractionation mode (SFD 5Gy, TFD 25Gy, 5 fractions) in the period from 01/01/2020 to 03/31/2022. The assessment of local control was carried out using positron emission tomography – computed tomography (PET-CT) from 18FDG. The intensity of the pain syndrome before and after radiation was assessed using a visual analog pain scale (VAS).

Results. 19 vertebrae with metastatic lesions were irradiated in 12 patients. The SBRT technique in hypofractionation mode was used in 6 (50 %) patients, in radiosurgery (SRS) mode was used in 4 (34 %) patients, in 2 (17 %) patients a combination of irradiation techniques was used on various affected segments of the spinal column. The general tumor volume (GTV) averaged 30.56 = 7.8 km2. When using the radiosurgical irradiation regimen, SFD ranged from 16 to 18 Gy. When using the hypofractionation technique, the total focal dose (TFD) was 25 Gy, a single focal dose (SFD) was 5 Gy.

Conclusion. Stereotactic radiation therapy and radiosurgery of metastatic vertebral tumors without compression of neural structures provides local tumor control in 92 % of patients within 6 months and in 83 % of patients within 1 year, regression of pain after irradiation – in 67 % of patients.

About the Authors

O. I. Kit
National Medical Research Centre for Oncology
Russian Federation

Oleg I. Kit – Academician at the Russian Academy of Sciences, Dr. Sci. (Med.), professor, general director, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-3061-6108, SPIN: 1728-0329, AuthorID: 343182, ResearcherID: U-2241-2017, Scopus Author ID: 55994103100


Competing Interests:

Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other conflicts of interest



D. E. Zakondyrin
National Medical Research Centre for Oncology
Russian Federation

Dmitry E. Zakondyrin – Cand. Sci. (Med.), PhD student of the Department of Neurooncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0002-0925-415X, SPIN: 7298-0181, AuthorID: 703429


Competing Interests:

Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other conflicts of interest



E. E. Rostorguev
National Medical Research Centre for Oncology
Russian Federation

Eduard E. Rostorguev – Dr. Sci. (Med.), head of the Department of Neurological Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-2937-0470, SPIN: 8487-9157, AuthorID: 794808, Scopus Author ID: 57196005138


Competing Interests:

Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other conflicts of interest



P. G. Sakun
National Medical Research Centre for Oncology
Russian Federation

Pavel G. Sakun – Cand. Sci. (Med.), head of Radiotherapy Department No. 2, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0001-8061-6259, SPIN: 3790-9852, AuthorID: 734600, Scopus Author ID: 56531945400


Competing Interests:

Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other conflicts of interest



V. I. Voshedskii
National Medical Research Centre for Oncology
Russian Federation

Vitalii I. Voshedskii – Cand. Sci. (Med.), radiotherapist of Radiotherapy Department No. 2, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0000-0003-1405-8329, SPIN: 4732-4005, AuthorID: 1032685, ResearcherID: Q-6122-2019, Scopus Author ID: 57215970384


Competing Interests:

Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other conflicts of interest



M. A. Komandirov
National Medical Research Centre for Oncology
Russian Federation

Maksim A. Komandirov – medical physicist at the Radiotherapy Department No. 2, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation

ORCID: https://orcid.org/0009-0008-0273-9737, SPIN: 9331-1278, AuthorID: 843316, Scopus Author ID: 36952848600


Competing Interests:

Kit O. I. has been the member of the editorial board of the South Russian Journal of Cancer since 2019, however he has no relation to the decision made upon publishing this article. The article has passed the review procedure accepted in the journal. The authors did not declare any other conflicts of interest



References

1. Zaborovsky NS, Ptashnikov DA, Topuzov EE, Levchenko EV, Mikhailov DA, Natalenko KE. Spine tumor epidemiology in patients who underwent orthopaedic surgery. Traumatology and Orthopedics of Russia. 2019;25(1):104–112. (In Russ.). https://doi.org/10.21823/2311-2905-2019-25-1-104-112, EDN: ZELXRB

2. Аrseniev AI, Kanaev SV, Novikov SN, Barchuk AA, Ponomareva OI, Antipov PhE, et al. Stereotactic radiation therapy in the treatment of primary and metastatic tumor lesions of the spine. Voprosy Onkologii. 2022;68(4):413–426. (In Russ.). https://doi.org/10.37469/0507-3758-2022-68-4-413-426, EDN: EYPWKT

3. Golanov AV, Gorlachev GE, Antipina NA, Konovalov NA, Shevelev IN, Vetlova ER, et al. Cyberknife stereotactic radiotherapy for mass lesions of spinal cord and spine. Zhurnal Voprosy Burdenko's Journal of Neurosurgery. 2012;76(1):54-63. (In Russ.). EDN: PDXHUL

4. Cox BW, Spratt DE, Lovelock M, Bilsky MH, Lis E, Ryu S, et al. International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e597-605. https://doi.org/10.1016/j.ijrobp.2012.03.009

5. Heron DE, Saiful Huq M, Herman JM. Stereotactic radiosurgery and stereotactic body radiation therapy (SBRT). Vargo JA, Mihai А, Engh JA et al. Spine SBRT. New York: Demos, 2018:279–292.

6. Sprave T, Verma V, Förster R, Schlampp I, Bruckner T, Bostel T, et al. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2018 Aug;128(2):274–282. https://doi.org/10.1016/j.radonc.2018.04.030

7. Ryu S, Deshmukh S, Timmerman R, Movsas B, Gerszten P, Yin F, et al. Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology/RTOG 0631. Int J Radiat Oncol Biol Phys. 2019 Aug 1;105(1):S2–3.

8. A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage M, et al. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021 Jul;22(7):1023–1033. https://doi.org/10.1016/S1470-2045(21)00196-0

9. Singh R, Lehrer EJ, Dahshan B, Palmer JD, Sahgal A, Gerszten PC, et al. Single fraction radiosurgery, fractionated radiosurgery, and conventional radiotherapy for spinal oligometastasis (SAFFRON): A systematic review and meta-analysis. Radiother Oncol. 2020 May;146:76–89. https://doi.org/10.1016/j.radonc.2020.01.030


Review

For citations:


Kit O.I., Zakondyrin D.E., Rostorguev E.E., Sakun P.G., Voshedskii V.I., Komandirov M.A. Experience of stereotactic radiation therapy and radiosurgical treatment of metastatic vertebral tumors. South Russian Journal of Cancer. 2024;5(2):6-13. https://doi.org/10.37748/2686-9039-2024-5-2-1. EDN: gjahux

Views: 431


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2686-9039 (Online)